

<u>P3-MumBubVax</u>: Development of a multi-component antenatal intervention to promote maternal and childhood vaccine uptake in Australia

A/Prof. Margie Danchin

Murdoch Children's Research Institute / University of Melbourne / Royal Children's Hospital


Dr. Jessica Kaufman

Murdoch Children's Research Institute / University of Melbourne

7th Vaccine Acceptance Meeting, Mérieux Foundation

23-25 September, 2019





Burden of disease for pregnant women and their infants

Influenza in pregnancy


- Pregnant women and infants are a WHO high-risk priority group for influenza¹
- Pregnant women are more than twice as likely to develop serious complications and be admitted to hospital than non-pregnant women, particularly if they have underlying illnesses
- Infants <6 months old are at highest risk of death or developing serious complications</p>
- The rates of hospitalisation in infants 0-5 months are 4 times higher than adults >75 years

Pertussis in pregnancy

- Risk to the pregnant woman herself is less than for influenza, but can be severe or lifethreatening for babies under 6 months
- Infants <3 months have the highest risk of pertussis-related death</p>



Promotion of maternal and childhood vaccines in the antenatal period



- Need to increase and <u>sustain</u> acceptance and uptake of antenatal vaccination for influenza (40-60%)⁶ and pertussis (65-80%)^{7,8}
- Prepare for new maternal vaccines
- Expectant parents begin to decide about childhood vaccines, beginning with birth hep B⁹
- Midwives in public antenatal clinics are most frequently accessed and highly trusted regarding vaccination⁹
- A robust vaccine program needs high levels of vaccine acceptance, where people understand and have confidence in the purpose, value and effectiveness of vaccines.

We need effective, scalable interventions to embed vaccination discussion and delivery into routine antenatal care





Interventions to improve antenatal influenza vaccine uptake - what works?

- Interventions that primarily aim to change vaccine attitudes
 - generally not effective in isolation
 - content that reinforces benefit to infant shown greatest impact
- Provider recommendation strongest predictor of vaccine receipt for pregnant women
 - few interventions evaluated focus on provider-patient interaction OR communication training for providers



- Nudge-based interventions have shown good success
 - include provider prompts to vaccinate and record vaccination, patient prompts ie text messages
 AND standing orders
 - build on positive intentions to vaccinate without trying to change attitudes
- Provision of vaccines on site
 - most common barrier is financial; need to fund/stock vaccines on site




The P3 Model - a promising intervention model

Theory-based model of preventive health behaviour that incorporates practice-, providerand patient-level factors¹¹

Designed for the USA private obstetric antenatal setting targeting obstetricians to improve antenatal influenza and pertussis uptake

Trial underway; pilot study showed non-significant but promising results¹²



Aims and research plan

- Design multi-component intervention package with and for midwives to optimise vaccine discussions
 - "MidVaxCom" qualitative study, Nov 2017-Sept 2018, Victoria and Western Australia
- Pilot the intervention to assess its acceptability and feasibility
 - "MumBubVax" pilot study, Oct 2018-September 2019, Victoria
- Evaluate intervention efficacy in a national cluster randomised controlled trial
 - "MumBubVax" RCT, from 2020, national

MidVaxCom - qualitative study to inform intervention design

- 12 semi-structured interviews with midwives.
 - Royal Women's Hospital, Melbourne (no maternal vaccines delivered)
 - King Edward Memorial Hospital, Perth (maternal vaccines delivered)
 - Discussed attitudes and values, perceptions about their role, communication techniques, resources and training, record-keeping

2 focus groups

 Discussed preliminary intervention features, design, appropriateness, usefulness





Led by Dr Katie Attwell Funded by WA Health









MidVaxCom - key findings

- Vaccination is part of a midwife's role, but limited time and competing priorities
- Roles and vaccine discussions vary when vaccines are available on site
- Very little/no specific vaccination training
- Generally comfortable recommending vaccination ("It is recommended") but not always confident answering questions
- Relationship with women is paramount, but most midwives respectfully ask parents' reasons for hesitancy or refusal
- Trustworthy online info and fact sheets are useful and valued
- Rarely discuss infant and childhood vaccines
- Midwives particularly interested in knowing key vaccine facts and how to debunk myths / misinformation
- Findings support and echo those in other Australian studies^{14,15}



P3-MumBubVax intervention development

 P3-MumBubVax intervention package - design informed by MidVaxCom qualitative research and studies from the USA^{11,12,16,17}

Practice-level components

- Vaccine champions
- Sticker/EMR reminders
- Vaccine promotional materials for clinic

Provider-level components

- Online vaccine and communication tutorial for midwives (VaxChat Australia)
- Learning exercise to create personalised vaccine fact 'cheat sheet'
- Provider portal of MumBubVax website with vaccine fact sheets and links to childhood vaccine info (SKAI)

Parent-level components

- Text message reminders after booking visit
- Parent portal of MumBubVax website with maternal and early childhood vaccine information and fact sheets

Vaccine
Uptake,
Acceptance &
Demand











PRACTICE LEVEL: Stickers for paper records and vaccine champions








YOU	JR PROG	RESS					WOMAN'S N	AME		
	ROUGH F		IA NC	/			UR NUMBE			
	(000111	KLON	IA I TO I				UR NUMBE	R		
VISIT 3			FUNDAL			PRESENTATION				
DATE /	GESTATION	PRESSURE	HEIGHT	FHR	FM	& STATION	NEXT VISIT U	RINALYSIS	OTHER	
Commen	ts .			_						_
	FLU VACCIN Discussed: Date: Received: Date: Declined:				<		M			
Print nar	ne		Signati	ure	/ 4		Designation		Interpreter used	Y/N
VISIT 4		BLOOD	FUNDAL			PRESENTATION				
VISIT 4 DATE	GESTATION	PRESSURE	HEIGHT	FIR	FM	PRESENTATION & STATION	NEXT VISIT U	RINALYSIS	OTHER	
Commen			W	1						
	•	٠,								
Print nar										
	ne		Signati	ure			Designation		Interpreter used	Y/N
VISIT 5		BLOOD PRESSURE	FUNDAL		FM	PRESENTATION & STATION		IRINA I YSIS		Y/N
VISIT 5 DATE	GESTATION	BLOOD PRESSURE		FHR	FM	PRESENTATION & STATION		IRINALYSIS		Y/N
DATE	GESTATION	BLOOD PRESSURE	FUNDAL		FM	PRESENTATION & STATION		IRINALYSIS		Y/N
DATE / /	GESTATION	BLOOD PRESSURE	FUNDAL	FHR	FM	PRESENTATION & STATION		IRINALYSIS		
Commen	GESTATION	PRESSURE	FUNDAL HEIGHT Signati	FHR	FM	& STATION	NEXT VISIT U	IRINA LYSIS	OTHER	
Print nar VISIT 6 DATE	GESTATION	BLOOD	FUNDAL HEIGHT	FHR	FM	PRESENTATION & STATION PRESENTATION STATION	NEXT VISIT U		OTHER Interpreter used	
Print nar VISIT 6 BATE / / /	GESTATION GESTATION	BLOOD	FUNDAL HEIGHT Signati	FHR		& STATION PRESENTATION	NEXT VISIT U		OTHER Interpreter used	
Print nar	GESTATION GESTATION	BLOOD	FUNDAL HEIGHT Signati	FHR		& STATION PRESENTATION	NEXT VISIT U		OTHER Interpreter used	
DATE / / / Commen Print nar VISIT 6 DATE / / /	GESTATION GESTATION GESTATION	BLOOD	FUNDAL HEIGHT Signati	FHR		& STATION PRESENTATION	NEXT VISIT U		OTHER Interpreter used	Y/N
Print nar VISIT 6 DATE / / / Commen	GESTATION GESTATION	BLOOD PRESSURE GESTATI best describe haven't in the	FUNDAL HEIGHT Signate FUNDAL HEIGHT Signate ON s your currers s pregnancy	FHR FHR vire	FM	PRESENTATION PRESENTATION STATION	Designation NEXT VISIT U Designation Designation implication in the same of	No. c	OTHER Interpreter used	Y/N
Print nara VISIT 6 DATE Print nara VISIT 6 DATE Print nara Print nara Quitable Date	GESTATION GESTATION	BLOOD PRESSURE GESTATI best describe haven't in thi nding out I w	Signature Signat	FHR FHR y t	FM	PRESENTATION STATION I started a lam smo	Designation NEXT VISIT U Designation Designation implication in the same of	No. c	Interpreter used OTHER Interpreter used of cigarettes per day of cigarettes per day	Y/N

PROVIDER LEVEL: VaxChat online training video



PROVIDER LEVEL: Personalised vaccine fact 'cheat sheet'

VaxChat Australia cheat sheet

In your conversations with expectant parents, it is helpful to have 1-2 key facts about maternal influenza and pertussis vaccines and the birth hepatitis B vaccine that you can share quickly and confidently with expectant parents.

In this short exercise, you will select the fact you think will be most memorable or useful in your discussions. At the end of the exercise, you will receive an email with your personalised fact cheat sheet, which you can print and insert into your ID lanyard for easy access. We will not use or store your email address or responses to any of the questions.

All the facts listed in this exercise are supported by reliable, recent evidence and are included on the MumBubVax website and in the VaxChat educational tutorial.

* Required

Email address *

Your email

First name

Your answer

GENERAL VACCINE SAFETY FACTS

In this question, you will select a key fact that you would like to remember about vaccine safety in general.

Choose 1 GENERAL vaccine safety fact

- O Maternal flu and pertussis vaccines are inactivated and can't cause
- 11% of women have mild reactions (local reactions, headache, fever)
- O Vaccines are tested in 3 phases of clinical trials before use and adverse events are monitored
- 1 in a million women have an anaphylactic reaction to vaccines









Jess test, this is your personalised vaccine information 'cheat sheet'. Please print this document, cut along the outside lines and fold down the centre. This small card is designed to fit in a plastic ID lanyard for easy access.



This is a personalised 'cheat sheet' with key facts about maternal influenza and pertussis and infant hepatitis B vaccines for you to share with parents mumbubvax.org.au

General vaccine safety fact:

· Vaccines are tested in 3 phases of clinical trials before use and adverse events are monitored

Flu facts:

- Flu complications include pneumonia, bronchitis, brain or heart inflammation & sepsis
- Maternal flu vaccination does not increase risk of stillbirth, premature delivery, or birth defects
- Flu vaccine effectiveness can vary each year, but vaccination is still the best way to protect mums & babies

Pertussis facts:

- · Pertussis complications include pneumonia, organ failure, seizures & brain damage from lack of oxygen
- · Previous anaphylactic reaction to vaccine is the only medical contraindication to maternal pertussis vaccination
- Protective antibodies transfer from mums to babies through the placenta after antenatal vaccination

Hepatitis B facts:

- Hepatitis B is very contagious & can be passed through birth, breastfeeding, biting & open sores
- No increased risk of Sudden Infant Death Syndrome (SIDS), autism, fever or infection from hepatitis B vaccination
- Premature babies are even more vulnerable to infection than full-term babies & should still be vaccinated on-schedule

Cut along this outside border ⋈


PRACTICE LEVEL: Text message reminders for mothers


- Personalised
- Delivered from a recognised authority
- Starts with a message about disease severity and then a message of self-efficacy

PROVIDER & PARENT LEVEL: MumBubVax website



PARENT LEVEL: Downloadable fact sheets





The hepatitis B vaccine for newborns MumBubVax Read more about immunisation for pregnant women and their bables at MumBubVax.org.au Bables under one year who catch hepatitis B can develop chronic hepatitis B, which can lead to liver disease and liver cancer in adulthood. Bables are most at risk of catching hepatitis B at birth.

bables inder only eye who cach repeats a card evereop chronic hepatitis B, which can lead to liver disease and liver cancer in adulthood. Bables are most at risk of catching hepatitis B at birth, which is why it is recommended that all bables are vaccinated against hepatitis B within 24 hours of being born. In Australia, the vaccine is free for all newborn bables.

How will hepatitis B affect my baby?

Hepatitis B is a serious infectious disease that mainly affects the liver¹. Around 90 per cent of bables who catch hepatitis B at birth will develop chronic hepatitis B, a condition that can lead to liver disease and liver cancer². There is no cure for chronic hepatitis B infection and people with the disease need long-term

chronic hepatitis B infection and people with the disease need long-term antiviral therapy to reduce the risk of developing liver cancer¹. Around one in four babies who catch hepatitis B at birth or soon after will die of liver failure or liver cancer as an adult⁴.

How does hepatitis B affect adults, including pregnant women?

The risk of developing chronic hepatitis B is far greater in babies than it is in dultis¹—leas than 10 per cent of infected adults develop chronic hepatitis B. Most adults who are infected with the hepatitis B virus recover fully. While infected, they may have no symptoms at all or very mild flu-like symptoms, or they may suffer from fever, nausea and vomitting, pain in the liver, pain in the joints and yellowing of the skin (called 'jaundice'). Many people who are carrying hepatitis B don't know that they

and vorticing, pain in the lever, pain in the joints and yellowing of the skin (called 'jaundice'). Many people who are carrying hepatitis B don't know that they have the virus.

How effective is the hepatitis B vaccine? Between 90 and 95 per cent of people under 40

Between 90 and 95 per cent of people under 40 who have had three doses of the hepatitis B vaccine, as recommended in the National Immunisation Program, are protected against the hepatitis B virus⁵.



For more information, you can call the National Immunisation Hotline on 1800 671 811.

The vaccine works by training the baby's immune system to recognise and get rid of the hepatitis B virus. The vaccine contains 'antigens' which are tiny fragments of the hepatitis B virus. When a baby's immune system detects the antigens in the vaccine, it produces antibodies to flight them and get rid of them. The vaccine does not contain any blood products and is not a live 'vaccine. The synthetic fragments cannot reproduce themselves or cause disease.

If you have any worries about how you feel after your vaccination, you can get help from your doctor, or your nearest emergency department, or by calling Health Direct on 1800 022 222.

References


For links to the references used in this factsheet, please go to MumBubVax.org.au.





Links to existing Sharing Knowledge About Immunisation (SKAI) resources about childhood vaccination





http://www.talkingaboutimmunisation.org.au/parents

P3-MumBubVax intervention designed to...

- Fit with midwife values
- Increase efficiency of vaccine conversations without adding to time or workload
- Schedule vaccine discussions at set times in pregnancy
- Create a platform for new vaccines ie RSV, GBS
- Operate in combination with structural levers





MumBubVax pilot for feasibility and acceptability

SETTING:

Royal Women's Hospital, Melbourne

TIMELINE:

October 2018 - September 2019

OUTCOMES:

- Feasibility, acceptability, degree of intervention implementation
- Uptake of maternal, infant and childhood vaccinations

MIDWIVES:

- n=25 midwives enrolled
- n=18 completed VaxChat training (72%)
- Median time to training completion = 13 days (range 5-53)

MOTHERS:

- n=62 expectant mothers enrolled (50% primipara)
- Data collection complete, analysis underway



Pilot data - quotes from midwives

Stickers are my favourite strategies!

It encouraged me to feel confident when discussing facts and figures with parents

Which skills from VaxChat did you use most?

I took more time to get to the root of people's concerns and use more open ended questions when discussing vaccinations.

Sticking to one key point and making that relevant to the woman's situation Really enjoyed the MumBubVax study. It increased my confidence in having these discussions and I have found the resources very helpful.









Next steps: national cluster RCT

P3-MumBubVax

Practice-level components

Provider-level components

Parent-level components

PROPOSED TRIAL OUTCOMES:

- 1. Uptake of maternal influenza vaccine during pregnancy (primary outcome)
- 2. Uptake of maternal pertussis vaccine during pregnancy
- Infant uptake of the birth dose of hepatitis B vaccine
- 4. Uptake and timeliness of primary series childhood vaccines to 12 months of age
- 5. Maternal knowledge and attitudes about maternal vaccines and hesitancy about childhood vaccines
- 6. Provider confidence in communicating about vaccination







References

- 1. WHO. Vaccines against influenza WHO position paper November 2012. Wkly Epidemiol Rec. 2012;87(47):461-476.
- 2. Mertz D, et al. Pregnancy as a risk factor for severe outcomes from influenza virus infection: A systematic review and meta-analysis of observational studies. Vaccine. 2017;35(4):521-8.
- 3. Fell DB, et al. Maternal influenza and birth outcomes: systematic review of comparative studies. BJOG. 2017;124(1):48-59
- 4. Li-Kim-Moy J, et al. Australian vaccine preventable disease epidemiological review series: Influenza 2006 to 2015. Commun Dis Intell Q Rep. 2016;40(4):E482-E95.
- 5. Winter K, et al. Risk factors associated with infant deaths from pertussis: a case-control study. Clin Infect Dis. 2015;61:1099-106.
- 6. Regan AK, et al., Trends in seasonal influenza vaccine uptake during pregnancy in Western Australia: Implications for midwives. Women and Birth. 2016;29(5): 423-429.
- 7. Data sourced from Clinical Council Unit, Safer Care Victoria. Data compiled by Health Protection Branch
- 8. Rowe SL, et al. Uptake of pertussis vaccine among pregnant women in Victoria, Australia: Temporal, geographical and socioeconomic variation. ESPID Meeting, Malmo, May 28-June 2 2018.
- 9. Danchin MH, et al. Vaccine decision-making begins in pregnancy: Correlation between vaccine concerns, intentions and maternal vaccination with subsequent childhood vaccine uptake. Vaccine. 2017;36(44):6473-6479.
- 10. Ellingson MK, et al. Enhancing uptake of influenza maternal vaccine. Expert Rev Vaccines. 2019 Feb;18(2):191-204.
- 11. Bednarczyk R, et al. Practice-, Provider-, and Patient-level interventions to improve preventive care: Development of the P3 Model. Preventive Medicine Reports. 2018;11:131-138.
- 12. Chamberlain AT, et al. Improving influenza and Tdap vaccination during pregnancy: A cluster-randomized trial of a multi-component antenatal vaccine promotion package in late influenza season. Vaccine. 2015;33(30):3571-9.
- 13. Kaufman J, Attwell K, Hauck Y, Omer SB, Danchin M. Vaccine discussions in pregnancy: interviews with midwives to inform design of an intervention to promote uptake of maternal and childhood vaccines. Human Vaccines and Immunotherapeutics 2019
- 14. Frawley JE, et al. Midwives' role in the provision of maternal and childhood immunisation information. Women and Birth. 2019.
- 15. Attwell K, et al. Is immunisation education in midwifery degrees adequate? Human Vaccines and Immunotherapeutics. 2018;00(00):1-4.
- 16. Dempsey AF, et al. Effect of a Health Care Professional Communication Training Intervention on Adolescent Human Papillomavirus Vaccination: A Cluster Randomized Clinical Trial. JAMA Pediatr. 2018;172(5):e180016.
- 17. Stockwell M, et al. Influenza vaccine text message reminders for urban, low-income pregnant women: A randomized controlled trial. American Journal of Public Health. 2014;104(SUPPL 1):7-12.

Melbourne Children's

murdoch
children's
research
institute



Thank you!

Research assistants (MumBubVax): Jacinta O'Sullivan, Jane Tuckerman

Study sites: The Royal Women's Hospital King Edward Memorial Hospital

Funding:

Communicable Disease Control
Directorate, WA Health
(MidVaxCom)
MCRI Infection and Immunity
Theme & Bell Charitable Fund
(MumBubVax)

Melbourne Children's

Excellence i clinical care research an education







